Table 2 Immunophenotype of blasts in CML with 11q23 translocations

2

Myeloid

60%

+: CD7, CD19 partial, CD13, CD33, CD34, CD38, HLA-DR, MPO

−: CD2, CD3, CD5, CD10, CD14, CD15, CD20, CD41, CD56, CD64, CD117, TdT

3

Myeloid

58%

+: CD13, CD33, CD38, CD64, HLA-DR, MPO (cytochemistry)

−: CD2, CD3, CD7, CD10, CD19, CD20, CD34, CD117,

4

Myeloid/T

60%

+: CD3(c), CD5, CD7, CD13, CD33, CD34, CD43, CD117, TdT, MPO

−: CD10, CD19, CD20

5

Myeloid

64%

+: CD4 partial, CD7 partial, CD13, CD15 subset, CD33, CD38, CD64, CD123, HLA-DR, MPO

−: CD2, CD3, CD5, CD10, CD14, CD19, CD22, CD34, CD36, CD41, CD56, CD117, TdT

6

Myeloid

80%

+: CD11c, CD13, CD33, CD34 weak, CD38, CD43, CD64, CD117, HLA-DR, MPO

−: CD3, CD19

7

Myeloid

47% (PB)

+: CD13, CD33, CD34 partial, CD38, CD64, CD117, HLA-DR, MPO

−: CD2, CD3, CD5, CD7, CD10, CD14, CD15, CD19, CD20, CD41, TdT

8

Myeloid

98%

+: CD13, CD33, CD34 partial, CD38, CD117, HLA-DR, MPO (3% by cytochemistry)

−: CD2, CD5, CD7, CD10, CD14, CD19, CD20, CD41, CD64, TdT

9

Myeloid

81%

+: CD7, CD13, CD33, CD34, CD38, CD64, CD117, MPO, TdT

−: CD2, CD3, CD10, CD19, CD20, HLA-DR

10

Myeloid

50%

+: CD10, CD13, CD22 (c), CD33, CD34, CD38, HLA-DR, TdT partial

−: CD2, CD3, CD19, CD41, CD64, CD117, MPO

11

Myeloid

36%

+: CD4, CD13, CD15, CD33, CD34 partial, CD38, CD64, CD117, CD123, MPO

−: CD2, CD3, CD5, CD7, CD14, CD19, CD22, CD36, CD56, HLA-DR, TdT